---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-197489"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:58:30.606208+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intellia raises ~$194.6M in public offering of 16.7M shares at $10.75; preliminary cash $517.2M as of March 31

## Summary
- Offered 16,744,187 shares at $10.75/share; underwriters exercised full option for 2,511,628 additional shares; net proceeds ~$194.6M.
- Proceeds will advance clinical development and commercial launch prep for lonvoguran ziclumeran (HAE), pipeline R&D, and potential acquisitions.
- Preliminary unaudited cash, cash equivalents and marketable securities as of March 31, 2026: ~$517.2M; raised $33.6M from ATM program in Q1.
- Company expects combined cash to fund expenses into 2028, excluding potential HAE product revenue, milestone payments, or strategic capital.
- Potential FDA approval of lonvoguran ziclumeran for hereditary angioedema anticipated in first half of 2027.

## SEC filing metadata
- accession: 0001193125-26-197489
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/0001193125-26-197489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/d308328d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-197489
- JSON: https://secwatch.observer/filing/0001193125-26-197489.json
- Plain text: https://secwatch.observer/filing/0001193125-26-197489.txt

## Source-grounded claims
- claim_id: 3c54501152111bcfa97dec58c4726bcbc91768b2
  claim: Intellia Therapeutics, Inc. reported preliminary financial results for quarter ended March 31, 2026.
  evidence_excerpt: On April 27, 2026, the Company disclosed in a preliminary prospectus supplement related to the Offering that its preliminary unaudited cash, cash equivalents and marketable securities as of March 31, 2026 were approximately $517.2 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/0001193125-26-197489-index.htm
- claim_id: 0606be06ed8108fac6462f321f55014da1721fb6
  claim: Intellia Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. valued at approximately $194.6 million (effective 2026-04-28).
  evidence_excerpt: On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/0001193125-26-197489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.